Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $79.00.
A number of research firms have weighed in on VERA. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. HC Wainwright boosted their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Evercore set a $91.00 target price on shares of Vera Therapeutics in a research report on Friday.
Get Our Latest Report on Vera Therapeutics
Vera Therapeutics Stock Performance
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the previous year, the company posted ($0.81) EPS. As a group, sell-side analysts forecast that Vera Therapeutics will post -5.9 EPS for the current fiscal year.
Insider Activity
In other Vera Therapeutics news, insider William D. Turner sold 2,187 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at $1,902,239.74. The trade was a 4.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the transaction, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This represents a 4.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 74,941 shares of company stock worth $3,096,592. Insiders own 15.90% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Quantinno Capital Management LP raised its position in shares of Vera Therapeutics by 72.6% during the first quarter. Quantinno Capital Management LP now owns 25,639 shares of the company’s stock valued at $1,031,000 after buying an additional 10,784 shares during the last quarter. SummitTX Capital L.P. acquired a new position in shares of Vera Therapeutics during the first quarter valued at about $814,000. Orbimed Advisors LLC raised its position in shares of Vera Therapeutics by 4.6% during the first quarter. Orbimed Advisors LLC now owns 369,596 shares of the company’s stock valued at $14,869,000 after buying an additional 16,096 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Vera Therapeutics by 136.5% during the first quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock valued at $18,397,000 after buying an additional 263,900 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of Vera Therapeutics by 114.2% during the first quarter. Sei Investments Co. now owns 13,001 shares of the company’s stock valued at $523,000 after buying an additional 6,932 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Read More
- Five stocks we like better than Vera Therapeutics
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
